FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

McCracken Joseph S 		2. Issuer Name and Ticker or Trading Symbol

Nexvet Biopharma plc [ NVET ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O NEXVET BIOPHARMA PLC, UNIT 5, SRAGH TECHNOLOGY PARK, RAHAN RD 		3. Date of Earliest Transaction (MM/DD/YYYY)

9/30/2016
(Street)

TULLAMORE, L2 R35 FR98
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares   9/30/2016     M    500   A $.125   11300   D  
 

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Share Units   $.125   9/30/2016     M         500      (1) 7/1/2019   Ordinary Shares   500   $0   1500   D  
 

Explanation of Responses:
( 1)  500 of the Restricted Share Units vested and became convertible on 9/30/16, and 500 Restricted Share Units shall vest and become convertible on each of 12/31/16, 3/31/17 and 6/30/17, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
McCracken Joseph S
C/O NEXVET BIOPHARMA PLC
UNIT 5, SRAGH TECHNOLOGY PARK, RAHAN RD
TULLAMORE, L2 R35 FR98 		X



Signatures
/s/ Joseph S. McCracken by Geraldine T. Farrell, Attorney-in-Fact 10/3/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more NEXVET BIOPHARMA PLC Charts.
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more NEXVET BIOPHARMA PLC Charts.